Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Monoclonal Gammopathy of Undetermined Significance 1Liver Cirrhosis 1Glioma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Urination × 1 year × Clear all
NCT03951220 2025-08-19

LOOMIS

Oxford University Hospitals NHS Trust

Completed
67 enrolled 24 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡